Taito City

Researchers are studying how mild and moderate liver impairment affect the way the body processes tasurgratinib after a single dose. This Phase 1 study compares participants with liver impairment to healthy individuals matched by age, race, gender, and body weight to better understand the drugs behavior in these groups. Participants with mild liver impairment receive a single 35 mg tablet of tasurgratinib after fasting overnight. Those with moderate impairment take a lower dose of 10 mg as two 5 mg capsules under the same fasting conditions. Healthy participants receive a 35 mg tablet and serve as a control group to compare drug effects. During the study, participants are monitored for how much tasurgratinib and its metabolites appear in their blood over 144 hours after dosing. Researchers measure peak concentrations, total drug exposure, time to peak, half-life, clearance, and volume of distribution. Safety tests include physical exams, ECGs, and lab tests. The study aims to complete by November 2026.